204 related articles for article (PubMed ID: 37998380)
1. Elucidation of GPR55-Associated Signaling behind THC and LPI Reducing Effects on Ki67-Immunoreactive Nuclei in Patient-Derived Glioblastoma Cells.
Kolbe MR; Hohmann T; Hohmann U; Maronde E; Golbik R; Prell J; Illert J; Strauss C; Dehghani F
Cells; 2023 Nov; 12(22):. PubMed ID: 37998380
[TBL] [Abstract][Full Text] [Related]
2. THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.
Kolbe MR; Hohmann T; Hohmann U; Ghadban C; Mackie K; Zöller C; Prell J; Illert J; Strauss C; Dehghani F
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802282
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
Obara Y; Ueno S; Yanagihata Y; Nakahata N
PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
[TBL] [Abstract][Full Text] [Related]
4. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Nevalainen T; Irving AJ
Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
[TBL] [Abstract][Full Text] [Related]
5. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
6. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
[TBL] [Abstract][Full Text] [Related]
8. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
[TBL] [Abstract][Full Text] [Related]
10. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
[TBL] [Abstract][Full Text] [Related]
11. What is the natural ligand of GPR55?
Okuno T; Yokomizo T
J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
[TBL] [Abstract][Full Text] [Related]
13. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Sharir H; Abood ME
Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
[TBL] [Abstract][Full Text] [Related]
16. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
Yang H; Zhou J; Lehmann C
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
[TBL] [Abstract][Full Text] [Related]
17. GPR55 ligands promote receptor coupling to multiple signalling pathways.
Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
[TBL] [Abstract][Full Text] [Related]
18. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.
AlSuleimani YM; Hiley CR
Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040
[TBL] [Abstract][Full Text] [Related]
19. The Mechanisms of GPR55 Receptor Functional Selectivity during Apoptosis and Proliferation Regulation in Cancer Cells.
Akimov MG; Gretskaya NM; Dudina PV; Sherstyanykh GD; Zinchenko GN; Serova OV; Degtyaryova KO; Deyev IE; Bezuglov VV
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982628
[TBL] [Abstract][Full Text] [Related]
20. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.
Leo LM; Familusi B; Hoang M; Smith R; Lindenau K; Sporici KT; Brailoiu E; Abood ME; Brailoiu GC
Neuroscience; 2019 Aug; 414():88-98. PubMed ID: 31279825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
